Seven Fleet Capital Management’s Context Therapeutics CNTX Stock Holding History

Seven Fleet Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$500K	Buy	+190,785	New	+$446K	0.16%	80

Other funds holding CNTX

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Seven Fleet Capital Management's CNTX Position: Q1 2026 in Review

Seven Fleet Capital Management opened a new position in Context Therapeutics (CNTX) in Q1 2026: 190,785 shares worth $500K. The stake represents 0.16% of the portfolio and ranks #80 among its holdings.

59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

Seven Fleet Capital Management held 190,785 shares of Context Therapeutics worth $500K as of Q1 2026.
Context Therapeutics was a new Seven Fleet Capital Management position in Q1 2026.
Context Therapeutics made up 0.16% of Seven Fleet Capital Management's portfolio in Q1 2026, its #80 holding.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.